Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers | Citedby Results | Molecular Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers

Mol Cancer Res (2020) 18 (7): 1050–1062.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients

Noemy Starita
Francesca Pezzuto
Sabrina Sarno
Nunzia Simona Losito
Sisto Perdonà
Luigi Buonaguro
Franco M. Buonaguro
Maria Lina Tornesello

International Journal of Cancer (2022) 150 (11): 1879.

Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma

Eduardo Nagore
Amaya Virós
Rajiv Kumar

Journal of Investigative Dermatology (2022) 142 (2): 279.

Clinical, environmental and histological distribution of BRAF , NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients*

E. Manrique‐Silva
S. Rachakonda
D. Millán‐Esteban
Z. García‐Casado
C. Requena
V. Través
R. Kumar
E. Nagore

British Journal of Dermatology (2021) 184 (3): 504.

TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer

Neeraj Agarwal
Sebastien Rinaldetti
Bassem B. Cheikh
Qiong Zhou
Evan P. Hass
Robert T. Jones
Molishree Joshi
Daniel V. LaBarbera
Simon R. V. Knott
Thomas R. Cech
Dan Theodorescu

Proceedings of the National Academy of Sciences (2021) 118 (38)

Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage

Alexandra M. Amen
Christof Fellmann
Katarzyna M. Soczek
Shawn M. Ren
Rachel J. Lew
Gavin J. Knott
Jesslyn E. Park
Andrew M. McKinney
Andrew Mancini
Jennifer A. Doudna
Joseph F. Costello

Proceedings of the National Academy of Sciences (2021) 118 (13)

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

Ivan de Kouchkovsky
Li Zhang
Errol J Philip
Francis Wright
Daniel M Kim
Divya Natesan
Daniel Kwon
Hansen Ho
Son Ho
Emily Chan
Sima P Porten
Anthony C Wong
Arpita Desai
Franklin W Huang
Jonathan Chou
David Y Oh
Raj S Pruthi
Lawrence Fong
Eric J Small
Terence W Friedlander
Vadim S Koshkin

Journal for ImmunoTherapy of Cancer (2021) 9 (5): e002127.

Occurrence, functionality and abundance of the TERT promoter mutations

Sivaramakrishna Rachakonda
Jörg D. Hoheisel
Rajiv Kumar

International Journal of Cancer (2021) 149 (11): 1852.

Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

Luca Fania
Dario Didona
Roberto Morese
Irene Campana
Valeria Coco
Francesca Romana Di Pietro
Francesca Ricci
Sabatino Pallotta
Eleonora Candi
Damiano Abeni
Elena Dellambra

Biomedicines (2020) 8 (11): 449.

TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends

Xiaotian Yuan
Mingkai Dai
Dawei Xu

Cancer Letters (2020) 493: 1.

Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma

Maria Giovanna Maturo
Sivaramakrishna Rachakonda
Barbara Heidenreich
Cristina Pellegrini
Nalini Srinivas
Celia Requena
Carlos Serra-Guillen
Beatriz Llombart
Onofre Sanmartin
Carlos Guillen
Lucia Di Nardo
Ketty Peris
Maria Concetta Fargnoli
Eduardo Nagore
Rajiv Kumar

Scientific Reports (2020) 10 (1)